compounding semaglutide lawsuit news Despite FDA ruling, compounded GLP-1s are still giving Novo and Lilly headaches on the market 🚨 FDA Moves to Permanently

**Results may vary

Delayed diagnosis of HCC with chronic alcoholic liver disease

I dont think that people are paying very close attention to those groups that have a higher degree of adiposity

Who should consider a cash-pay GLP-1 program Cash-pay GLP-1 programs typically suit individuals who: Have a BMI of 27 or higher with a weight-related comorbidity (high blood pressure, sleep apnea, prediabetes), or BMI of 30 or higher Have insurance that excludes weight loss medications, or have no prescription drug coverage Have tried lifestyle interventions without achieving sustained results Want the convenience and privacy of a fully telehealth-based experience Are comfortable with weekly self-injection (or are interested in oral/sublingual alternatives) GLP-1 medications are not appropriate for everyone

The ultimate goal for researchers in the ESSENCE trial was to find the right balance of semaglutide to resolve the damage caused by fat buildup in the liver (steatohepatitis) while at the same time to reduce scarring (fibrosis)